Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-11-07
2011-10-11
Yu, Misook (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388230, C530S391100, C530S391300, C530S391700
Reexamination Certificate
active
08034905
ABSTRACT:
Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.
REFERENCES:
patent: 5942385 (1999-08-01), Hirth
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6342221 (2002-01-01), Thorpe et al.
patent: 6416758 (2002-07-01), Thorpe et al.
patent: 6524583 (2003-02-01), Thorpe et al.
patent: 6676941 (2004-01-01), Thorpe et al.
patent: 6703020 (2004-03-01), Thorpe et al.
patent: 6887468 (2005-05-01), Thorpe et al.
patent: 7056509 (2006-06-01), Thorpe et al.
patent: 2005/0123537 (2005-06-01), Thorpe et al.
patent: 2006/0280747 (2006-12-01), Fuh et al.
patent: 0064946 (2000-11-01), None
patent: 03102157 (2003-12-01), None
Liang W.C. et al., “Cross-species Vascular Endothelial Growth Factor (VGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF,” Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, 281(2): 951-961, Jan. 13, 2006.
Klohs W. D. et al., “Antiangiogenic agents,” Current Opinion in Biotechnology, vol. 10, No. 6, pp. 544-549, 1999.
Fuh Germaine et al., “Structure-Function Studies fo Two Synthetic Anti-vascular Endothelial Growth Factor Fabs and Comparison with the Avastin Fab,” Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, Inc., vol. 281, No. 10, pp. 6625-6631, 2006.
Roland C.L. et al., “Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer,” PLoS ONE, vol. 4, issue 11, e7699, 13 pp., Nov. 2009.
Sullivan L.A. et al., “r84, a Novel Therapeutic Antibody against Mouse and Human VEGF with Potent Anti-Tumor Activity and Limited Toxicity Induction,” PLoS ONE, vol. 5, issue 8, e12031, 13 pages, Aug. 2010.
Roland C.L. et al., “Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts,” Mol Cancer Ther, 8(7): 1761-1771, 2009.
Sullivan L.A and Brekken R.A.,“The VEGF family in cancer and antibody-based strategies for their inhibition,” mAbs 2 (2):2, 165-175, 2010.
Brekken R.A. et al., “Vascular Endothelial Growth Factor as a Marker of Tumor Endothelium,” Cancer Research 58: 1952-1959, May 1, 1998.
Brekken R.A. et al., “Selective Inhibition of Vascular Endothelial Growth Factor (VGF) Receptor 2 (KD/Flk-1) Activity by a Monoclonal Anti-VEGF Antibody Blocks Tumor Growth in Mice,” Cancer Research 60: 5117-5124, Sep. 15, 2000.
Whitehurst B. et al., “Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model,” Int. J. Cancer, 121: 2181-2191, 2007.
Dineen S.P. et al., “Vascular Endothelial Growth Factor Receptor 2 Mediates Macrophage Infiltration Into Orthotopic Pancreatic Tumors in Mice,” Cancer Res 68(11): 4340-4346, 2008.
Kavlie A., et al., “Human antibodies specific for VEGF that selectively block activation of VEGFR2” (Poster) The 7th International Symposium on Anti-Angiogenic Agents, San Diego, California, Feb. 11-13, 2005.
Carbon et al., (Abstract) 98th Annual Meeting of the American Association for Cancer Research, Los Angeles, CA, USA, Apr. 14-18, 2007, “Blockade of tumor derived VEGF activation of VEGF receptor 2 reduces macrophage infiltration into tumors and decreases metastasis in a pre-clinical orthotopic model of pancreatic cancer”, Abstract publication: Proceedings of the American Association for Cancer Research Annual Meeting 48 p. 505-506 Apr. 2007. (Title of this talk was published on line on Feb. 20, 2007 and online publication of the abstract in Mar. 2007).
Carbon et al., “Blockade of tumor-derived VEGF activation of VEGF receptor 2 reduces macrophage infiltration into tumors and decreases metastasis in a pre-clinical orthotopic model of pancreatic cancer” (Poster) 98th Annual Meeting of the American Association for Cancer Research, Los Angeles, CA, USA, Apr. 14-18, 2007.
Brekken. (Oral presentation) IBC Life Sciences 5th Annual International Conference: Anti-angiogenesis, Boston, November 12-13, 2007, “Development of 2C3 as a Clinical Candidate for Inhibition of VEGF Activation of VEGF Receptor 2”, Nov. 12, 2007.
Kavlie et al., (Abstract) IBC Life Sciences 5th Annual International Conference, Antibody Therapeutics, Advancing Clinical and Preclinical Development of Therapeutic Antibodies and Antibody Conjugates, San Diego, Dec. 4-6, 2007 “Development and characterization of fully human anti-VEGF antibody fragments that selectivity inhibit VEGF Receptor 2 activity”.
Kavlie et al., (Poster) IBC Life Sciences 5th Annual International Conference, Antibody Therapeutics, Advancing Clinical and Preclinical Development of Therapeutic Antibodies and Antibody Conjugates, San Diego, Dec. 4-6, 2007 “Identification and characterization of fully human anti-VEGF antibody fragments and IgGs that selectively inhibit VEGF Receptor 2 activity”, poster available from Dec. 2-6, 2007.
Freimark, (Oral presentation) IBC Life Sciences 5th Annual International Conference, Antibody Therapeutics, Advancing Clinical and Preclinical Development of Therapeutic Antibodies and Antibody Conjugates, San Diego, Dec. 4-6, 2007, “Development of 2C3 as a Clinical Candidate for Inhibition of VEGF Activation of VEGF Receptor 2”, Dec. 5, 2007.
Kavlie et al., “Generating fully human antibodies that are improved with respect to cross reactivity profile and affinity compared to existing murine, chimeric or humanized antibodies” (Abstract) Protein Expression Europe & Antibodies Europe conference, Oct. 20-23, 2008, Lisbon.
Kavlie, (Oral Presentation) Protein Expression Europe & Antibodies Europe conference, Oct. 20-23, 2008, Lisbon, “Generating fully human antibodies that are improved with respect to cross reactivity profile and affinity compared to existing murine, chimeric or humanized antibodies”, Oct. 23, 2008.
Kavlie et al., “Generation of fully human anti-cancer antibodies with improved cross-reactivity and affinity profiles in comparison with existing murine, chimeric or humanized antibodies” (Abstract) The 25th International Conference: Advances in the Application of the Monoclonal Antibodies in Clinical Oncology and Symposium on Cancer stem Cells, Island of Rhodes, Greece, Jun. 16-18, 2008.
Kiprijanov, (Oral presentation) The 25th International Conference: Advances in the Application of the Monoclonal Antibodies in Clinical Oncology and Symposium on Cancer stem Cells, Island of Rhodes, Greece, Jun. 16-18, 2008, “Advances in the application of Monoclonal Antibodies in Clinical Oncology”, Jun. 16, 2008.
Payton et al., “Selective inhibition of VEGF receptor 2 activity with a fully human monoclonal anti-VEGF antibody blocks tumor growth in mice”(Abstract) 3rd Mayo Clinic Angiogenesis Symposium, Oct. 24-26, 2008.
Dellinger et al., “Novel Anti-VEGF Antibody Affects Stroma in Orthotopic Breast Cancer Xenografts” (Abstracts) 3rd Mayo Clinic Angiogenesis Symposium, Oct. 24-26, 2008.
Brekken, (Oral presentation) 3rd Mayo Clinic Angiogenesis Symposium, Oct. 24-26, 2008, “Selective blockade of VEGFR2 activity with a fully human anti-VEGF monoclonal antibody”, Oct. 25, 2008.
Welschof, (Oral presentation) European Life Science CEO Forum Investing & Partnering in Biotech—Medtech—Speciality Pharma & Emerging Markets C
Kavlie Anita
Schlunegger Kyle
Affitech Research AS
Duffy Brad
Peregrine Pharmaceuticals, Inc.
Rothwell Figg Ernst & Manbeck
Yu Misook
LandOfFree
Anti-VEGF antibody compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-VEGF antibody compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-VEGF antibody compositions and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4256930